{"nct_id":"NCT04044859","title":"ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-03","start_date":"2019-08-20","start_date_type":"ACTUAL","primary_completion_date":"2025-12-23","primary_completion_date_type":"ESTIMATED","completion_date":"2037-04-30","completion_date_type":"ESTIMATED","phases":["PHASE1"],"tickers":["ADAP"]}